Editas Medicine, Inc. (EDIT)
Automate Your Wheel Strategy on EDIT
With Tiblio's Option Bot, you can configure your own wheel strategy including EDIT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EDIT
- Rev/Share 0.3754
- Book/Share 0.7515
- PB 2.9539
- Debt/Equity 0.4988
- CurrentRatio 3.0752
- ROIC -0.9041
- MktCap 185842638.0
- FreeCF/Share -2.592
- PFCF -0.8633
- PE -0.7339
- Debt/Assets 0.1181
- DivYield 0
- ROE -1.6629
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EDIT | H.C. Wainwright | -- | Buy | -- | $3 | April 28, 2025 |
| Downgrade | EDIT | JP Morgan | Neutral | Underweight | -- | -- | Dec. 16, 2024 |
| Downgrade | EDIT | Chardan Capital Markets | Buy | Neutral | -- | -- | Dec. 13, 2024 |
| Downgrade | EDIT | Stifel | Buy | Hold | $11 | $3 | Dec. 13, 2024 |
| Downgrade | EDIT | Truist | Buy | Hold | -- | -- | Dec. 13, 2024 |
| Downgrade | EDIT | Wells Fargo | Overweight | Equal Weight | $7 | $4 | Dec. 11, 2024 |
News
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Read More
Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Editas Medicine, Inc. (NASDAQ:EDIT ) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Welcome to the last fireside for day 1 of the 2025 Bank of America Healthcare Conference. Thanks for joining this session with Editas.
Read More
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.
Read More
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Read More
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
Read More
Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Read More
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore O'Neill with us.
Read More
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Negative
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
Read More
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Alexander Kelly - TD Cowen Alexander Kelly Hi everyone. I'm Alex Kelly.
Read More
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.
Read More
About Editas Medicine, Inc. (EDIT)
- IPO Date 2016-02-03
- Website https://www.editasmedicine.com
- Industry Biotechnology
- CEO Dr. Gilmore O'Neill M.D.
- Employees 246